Trial Profile
A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety With the Comparator Humira in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms ARABESC
- Sponsors Fujifilm Kyowa Kirin Biologics
- 18 Feb 2021 Results published in the Viatris Inc Media Release
- 09 Jul 2020 According to a Mylan media release, based on this study, the U.S. Food and Drug Administration (FDA) has approved Hulio (adalimumab-fkjp), in both prefilled syringe and auto-injector presentations.
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism